Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 729 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Can Chemotherapy Drugs Be Designed to Avoid Side Effects? December 16, 2022 Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes June 3, 2022 Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... May 8, 2021 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 Load more HOT NEWS What to Do When You Are Diagnosed With Cancer During Pregnancy Targeted drug recommended to treat some advanced lung cancer patients Anal Cancer Incidence and Deaths Are Rising in the United States Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment
